MNOV Panoramica delle azioni MediciNova, Inc. è una società biofarmaceutica che si concentra sullo sviluppo di terapie innovative e di piccole molecole per il trattamento di gravi malattie con esigenze mediche insoddisfatte negli Stati Uniti. Maggiori dettagli
Analisi del rischio + 1 più rischio
Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
MediciNova, Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per MediciNova Prezzi storici delle azioni Prezzo attuale dell'azione US$1.99 Massimo di 52 settimane US$2.55 Minimo di 52 settimane US$1.12 Beta 0.84 Variazione di 1 mese -8.29% Variazione a 3 mesi 11.80% Variazione di 1 anno 32.67% Variazione a 3 anni -21.03% Variazione a 5 anni -71.45% Variazione dall'IPO -81.83%
Notizie e aggiornamenti recenti
Medicinova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver Nov 15
MediciNova, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Oct 30
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) Oct 01
MediciNova, Inc. Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition Aug 30
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth Aug 28
MediciNova, Inc. to Report Q2, 2024 Results on Aug 09, 2024 Jul 10 Vedi altri aggiornamenti
Medicinova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver Nov 15
MediciNova, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Oct 30
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) Oct 01
MediciNova, Inc. Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition Aug 30
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth Aug 28
MediciNova, Inc. to Report Q2, 2024 Results on Aug 09, 2024 Jul 10
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer Jun 06
MediciNova, Inc. Announces Data from Phase 1B/2A Clinical Trial of Mn-166 (Ibudilast) in Glioblastoma Patients At the American Society of Clinical Oncology (Asco) Annual Meeting 2024 Jun 05
MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome May 15
MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast) May 08
MediciNova, Inc., Annual General Meeting, Jun 11, 2024 Apr 28
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely Apr 19
MediciNova, Inc. to Report Q1, 2024 Results on May 10, 2024 Apr 12
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan Mar 27
Medicinova Announces New Data and Results of Mn-166 (Ibudilast) in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology Mar 12
Price target increased by 69% to US$27.00 Feb 22
MediciNova, Inc. to Report Fiscal Year 2023 Results on Feb 14, 2024 Jan 22
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China Jan 17
MediciNova, Inc. Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-Induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology Dec 22
MediciNova, Inc. Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe Dec 07
MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans Nov 27
MediciNova, Inc. to Report Q3, 2023 Results on Nov 10, 2023 Oct 08
Price target decreased by 41% to US$16.00 Aug 24
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology Aug 19 MediciNova, Inc. Receives A Notice of Intention to Grant for A New Patent Covering MN-166 (Ibudilast) for the Treatment of Macular Injury in Europe
Less than half of directors are independent Aug 13
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely Jul 11
MediciNova, Inc. Announces Presentation of Results from the Phase 2B Trial of Mn-166 (Ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting Jun 30
Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation Mar 18
MediciNova Announces Health Canada Grants Authorization to Commence Multi-Arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID Feb 09
MediciNova, Inc. Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder Jan 31
MediciNova, Inc. Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma Jan 13
MediciNova Receives Notice of Allowance for A New Patent Covering Mn-001 and Mn-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada Jan 12
MediciNova, Inc. Receives Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil Jan 10
MediciNova, Inc. Completes Phase I Clinical Trial to Evaluate MN-166 10 MG Intravenous Infusion in Healthy Volunteers Jan 06
MediciNova, Inc. Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presents at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation Dec 08
Price target decreased to US$13.00 Nov 16
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth Oct 12
MediciNova, Inc. to Report Q3, 2022 Results on Nov 11, 2022 Oct 06
MediciNova to get US patent for MN-166 to treat brain cancer Sep 15
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada Sep 14
MediciNova's MN-166 to be part of study to treat Long COVID Aug 16
First half 2022 earnings released Aug 12
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea Jul 28
MediciNova, Inc Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia Jul 27
MediciNova, Inc. to Report Q2, 2022 Results on Aug 12, 2022 Jul 24
MediciNova, Inc. Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast) Jul 22
MediciNova begins study of parenteral formulation of MN-166 Jul 22
MediciNova announces extension of BARDA contract for Ibudilast development Jun 30
MediciNova, Inc. Announces Executive Changes Jun 22 MediciNova, Inc. Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome Jun 09
Price target decreased to US$13.00 Apr 27
MediciNova, Inc. to Report Q1, 2022 Results on May 13, 2022 Apr 24
MediciNova, Inc. Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research Apr 21
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome Apr 13
MediciNova, Inc. Announces Plans for A Phase 2 Trial of Mn-001 (Tipelukast) in Nafld with Type 2 Diabetes Mellitus and Hypertriglyceridemia Apr 12
MediciNova, Inc. Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research Apr 08
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely Mar 19
MediciNova, Inc. announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs Feb 24
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada Feb 01
MediciNova Receives Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe Jan 28
MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS Dec 15
MediciNova, Inc. Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND Dec 11
Medicinova, Inc. Announces New Data Regarding Mn-166 (ibudilast) in Glioblastoma Presented At the 26Th Annual Meeting of the Society for Neuro-Oncology Nov 24
MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business Nov 23
MediciNova, Inc. Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND Aug 31
MediciNova: The Pain Of A Positive Outlook Aug 31
Price target decreased to US$16.00 Aug 27
Chief Medical Officer & Director exercised options to buy US$229k worth of stock. Aug 26
Consensus revenue estimates increase to US$15.5m Aug 19
Chief Financial Officer Edward Stepanow has left the company Aug 04 MediciNova, Inc.(NasdaqGM:MNOV) dropped from Russell 3000 Growth Index
MediciNova, Inc. Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal Jun 22
MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study Jun 21
MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury Jun 08
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth May 15
MediciNova, Inc. a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Europe May 06
The MediciNova Riddle: Worth Unravelling Apr 26
New 90-day high: US$8.74 Mar 11
MediciNova, Inc. Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-Induced Lung Injury Mar 10
MediciNova, Inc. Announces Update on SARS-CoV-2 Vaccine for Covid-19 Mar 05
Co-Founder exercised options to buy US$492k worth of stock. Mar 03
Analysts increase revenue estimates to US$39.5m Feb 27
New 90-day high: US$6.36 Feb 05
MediciNova, Inc. announced that it has received $19.999999 million in funding from 3D Investment Partners Pte. Ltd Feb 02
MediciNova, Inc. Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (Ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis in Japan Jan 20
MediciNova, Inc. announced that it expects to receive $19.999999 million in funding from 3D Investment Partners Pte. Ltd Jan 13
MediciNova inks $20M securities purchase agreement with 3D Investment Partners Jan 12
Medicinova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS Dec 30
MediciNova nabs new U.S. patent for ibudilast in multiple sclerosis Dec 29
MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans Dec 29 Rendimenti per gli azionisti MNOV US Biotechs US Mercato 7D -6.6% 1.2% 0.7% 1Y 32.7% -7.0% 23.0%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: MNOV ha superato il US Biotechs che ha restituito -7 % nell'ultimo anno.
Rendimento vs Mercato: MNOV ha superato il mercato US che ha restituito 23 % nell'ultimo anno.
Volatilità dei prezzi Is MNOV's price volatile compared to industry and market? MNOV volatility MNOV Average Weekly Movement 16.9% Biotechs Industry Average Movement 11.1% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.9% 10% least volatile stocks in US Market 3.1%
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di MNOV è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale di MNOV è aumentata da 11% a 17% nell'ultimo anno.
Informazioni sull'azienda MediciNova, Inc. è un'azienda biofarmaceutica che si concentra sullo sviluppo di terapie innovative e a base di piccole molecole per il trattamento di gravi malattie con esigenze mediche insoddisfatte negli Stati Uniti. L'azienda sta sviluppando MN-166 (ibudilast), un agente antinfiammatorio e neuroprotettivo orale per il trattamento di disturbi neurologici e di altro tipo, come la sclerosi multipla primaria e secondaria progressiva, la sclerosi laterale amiotrofica, la neuropatia periferica indotta da chemioterapia, la mielopatia degenerativa cervicale, il glioblastoma, la dipendenza da sostanze e la tossicodipendenza, nonché la prevenzione della sindrome da distress respiratorio acuto e la COVID lunga. La pipeline di prodotti dell'azienda comprende anche MN-221 (bedoradrina), un agonista selettivo dei recettori beta-2-adrenergici per il trattamento delle esacerbazioni acute dell'asma; MN-001 (tipelukast), un composto di piccole molecole biodisponibile per via orale per il trattamento di malattie fibrotiche e di altro tipo, tra cui la malattia del fegato grasso non alcolica e la fibrosi polmonare idiopatica; e MN-029 (denibulina), un agente legante la tubulina per il trattamento dei tumori solidi.
Mostra di più MediciNova, Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di MediciNova con la sua capitalizzazione di mercato? MNOV statistiche fondamentali Capitalizzazione di mercato US$97.60m Guadagni(TTM ) -US$10.29m Ricavi(TTM ) n/a
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) MNOV Conto economico (TTM ) Ricavi US$0 Costo del fatturato US$0 Profitto lordo US$0 Altre spese US$10.29m Guadagni -US$10.29m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -0.21 Margine lordo 0.00% Margine di profitto netto 0.00% Rapporto debito/patrimonio netto 0%
Come si è comportato MNOV nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/10 03:54 Prezzo dell'azione a fine giornata 2025/01/08 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche MediciNova, Inc. è coperta da 10 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione David Buck B. Riley Securities, Inc. Yen Ting Chen Credit Suisse Jason Kolbert D. Boral Capital LLC.
Mostra 7 altri analisti 
